Structure-activity relationships among hallucinogenic tryptamine derivatives evaluated by schedule-controlled behaviour

Harris, R. Adron; Homfeld, E.; Campaigne, E.

doi:10.1111/j.2042-7158.1981.tb13790.x

Cited by 4 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies investigate the effects of multiple compounds, comparing the effects of psilocybin with other serotonergic hallucinogens or stimulants; with these we report only the behavioural outcomes specific to psilocybin. In some studies, the effects of multiple compounds were tested in a single subject, with reported wash-out periods or intervals between drug administration ranging from 3 days (Harris et al, 1981) to 2 weeks (Roberts & Bradley, 1967). Since cross-tolerance has been demonstrated across various serotonergic psychedelics, in some instances there may be interference in behavioural measures when study drugs are administered within shorter wash-out periods.…”

Section: Resultsmentioning

confidence: 99%

“…These non-human animal studies revealed behavioural phenomenology of drug effect not captured in human clinical trials, providing a biological and behavioural basis for understanding psilocybin's potential therapeutic effect beyond the narrow and static conceptions of DSM-V based diagnostic categories. Psilocybin demonstrates a biphasic dose and time response, with decreases in behavioural response evidenced early followed by subsequent increases in hedonic Cameron & Appel, 1976Castellano, 1978Harris et al, 1981Hesselgrave et al, 2021Hesselgrave et al, 2021bHiggins et al, 2021Hurley et al, 2020Koerner & Appel, 1982Marquis et al, 1973Matsushima et al, 2009Rambousek et al, 2014Rech et al, 1975Sakloth et al, 2019Thompson, 2019 Guest & Consroe, 1979Horibe, 1974Horita & Weber, 1962Martin et al, 1978Meldrum & Naquet, 1971Schlemmer & Davis, 1986Sink et al, 1983Steiner & Sulman, 1963Sugrue, 1969Vaupel et al, 1979Wada, 1962Wilson et al, 1981 Sleep-Wake Behaviour N = 1 Thomas et al, 2020…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping Review

Shore,

Dobson,

Thomson

et al. 2024

Preprint

View full text Add to dashboard Cite

Background and Aims: Psilocybin is a psychedelic drug that may hold promise for a wide range of human health conditions, yet the identification of therapeutic processes and mechanisms of action remains exploratory. We conducted a scoping review on pre-clinical behavioural investigations of psilocybin in non-human animals to help determine the behavioural effects of psilocybin in non-human animals, to identify studies completed, behavioural tests employed, and what dosing modalities had been studied. Methods: A librarian-conducted literature search was performed using predefined key terms and search criteria and additional searching was conducted by reviewers, using electronic databases, grey literature sources, and reference lists of relevant articles or reviews. The final search updated occurred in October, 2021. Studies were reviewed, screened and selected against an a priori protocol using Covidence software by multiple reviewers with results plotted across the Research Domains Criteria construct. Results: From 4124 records identified by database searching, 260 publications were subjected to full-text review with 77 studies included in this scoping review, published between 1962-2021. The preponderance of studies (n=64) investigated behavioural outcomes in rodents. Only 43 studies (55.8%) reported on housing conditions, and seventeen studies (22.1%) failed to report sample size. All studies reported behavioural outcomes following drug administration, with fifty-one studies (66.2%) using psilocybin, thirty studies (42.9%) psilocin, four studies (5.2%) administering whole mushroom extracts (WME), and a further eight studies investigating both psilocybin and psilocin and one study reporting the effects of both psilocin and WME. One hundred and thirty distinct behavioural investigations using fifty different behavioral paradigms were identified. Few adverse events were reported, and even exceedingly high doses were apparently well tolerated. Conclusion: With seventy-seven publications spanning close to sixty years, there is huge variation in study design and quality. Overall psilocybin presents a unique and strong safety profile with no evidence of biological toxicity, is characterized by unique time and dose-dependent effects, and its pattern of drug action is significantly context and training-sensitive. Data suggest putative effects of psilocybin include acute arousal, dose-dependent sedation, reductions in fear conditioning at low doses, reduced aggression, improved valence, acute disruption of working memory, the rescuing of deficits from chronic stress, and improved learning when combined with repeated environmental exposure after resolution of drug effect. Keywords: psilocybin, psychedelic, non-human animal research, scoping review, behavioural research, Research Domains Criteria.

show abstract

Section: Resultsmentioning

confidence: 99%